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Abstract
Background:  The early stages of Alzheimer's disease (AD) are closely associated with the
production of the Aβ1–42 peptide, loss of synapses and gradual cognitive decline. Since some
epidemiological studies showed that EGb 761, an extract from the leaves of the Ginkgo biloba tree,
had a beneficial effect on mild forms of AD, the effects of some of the major components of the
EGb 761 extract (ginkgolides A and B, myricetin and quercetin) on synapse damage in response to
Aβ1–42 were examined.
Results: The addition of Aβ1–42 to cortical or hippocampal neurons reduced the amounts of cell
associated synaptophysin, a pre-synaptic membrane protein that is essential for neurotransmission,
indicating synapse damage. The effects of Aβ1–42 on synapses were apparent at concentrations
approximately 100 fold less than that required to kill neurons; the synaptophysin content of
neuronal cultures was reduced by 50% by 50 nM Aβ1–42. Pre-treatment of cortical or hippocampal
neuronal cultures with ginkgolides A or B, but not with myrecitin or quercetin, protected against
Aβ1–42-induced loss of synaptophysin. This protective effect was achieved with nanomolar
concentrations of ginkgolides. Previous studies indicated that the ginkgolides are platelet-activating
factor (PAF) receptor antagonists and here we show that Aβ1–42-induced loss of synaptophysin
from neuronal cultures was also reduced by pre-treatment with other PAF antagonists (Hexa-PAF
and CV6209). PAF, but not lyso-PAF, mimicked the effects Aβ1–42 and caused a dose-dependent
reduction in the synaptophysin content of neurons. This effect of PAF was greatly reduced by pre-
treatment with ginkgolide B. In contrast, ginkgolide B did not affect the loss of synaptophysin in
neurons incubated with prostaglandin E2.
Conclusion: Pre-treatment with ginkgolides A or B protects neurons against Aβ1–42-induced
synapse damage. These ginkgolides also reduced the effects of PAF, but not those of prostaglandin
E2, on the synaptophysin content of neuronal cultures, results consistent with prior reports that
ginkgolides act as PAF receptor antagonists. Such observations suggest that the ginkgolides are
active components of Ginkgo biloba preparations and may protect against the synapse damage and
the cognitive loss seen during the early stages of AD.
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Background
Alzheimer's disease (AD) is a complex and genetically het-
erogeneous disease that is the most common form of
dementia and affects up to 15 million individuals world-
wide. The amyloid hypothesis of AD pathogenesis main-
tains that the primary event is the production and
accumulation of amyloid-β (Aβ) peptides, derived from
abnormal proetolytic cleavage of the amyloid precursor
protein [1-3]. The accumulation of Aβ peptides leads to
the subsequent disruption of neuronal processes, abnor-
mal phosphorylation of tau and ultimately the dysfunc-
tion and death of neurons. However, the precise
mechanisms by which Aβ peptides lead to neuronal dam-
age remain to be fully determined. Initially it was thought
that fibril formation by Aβ peptides was required for neu-
rotoxicity [4], however, more recent studies showed that
smaller soluble oligomers of Aβ or Aβ-derived diffusible
ligands are also potent neurotoxins [5,6].
The early stages of AD are characterised by memory
impairment and subtle behavioural changes, associated
with changes in synaptic function and a reduction in the
levels of synaptophysin, a presynaptic membrane protein
essential for neurotransmitter release and the recycling of
synaptic vesicles [7], within the brain. These occur before
any gross neurological damage is observed [8-10]. The
loss of synapses and the reduction in synaptophysin levels
are features of AD that strongly correlate with cognitive
decline [11]. We previously developed an in vitro model to
examine the effects of Aβ peptides on synapses where the
amounts of synaptophysin in neuronal cultures were
measured as a surrogate marker of synapse function. The
addition of Aβ1–42 reduced the synaptophysin content of
neurons indicating the loss of synapses in these cultures
[12]. In this paper, a possible mechanism leading to Aβ1–
42-induced loss of synaptophysin from neuronal cultures
was investigated.
Extracts from the leaves of the Ginkgo biloba tree are
becoming increasingly popular as a treatment that is
claimed to reduce memory loss and the symptoms of mild
cognitive disorders including AD [13-15]. However, there
remains considerable controversy regarding the mecha-
nisms of action of these preparations, or even whether
such preparations have any clinical benefit. While some
published studies conclude that the use of a standardized
extract of the leaves of the Ginkgo biloba tree (EGb 761)
reduces the symptoms of mild cognitive disorders includ-
ing AD [13,16], other studies have failed to show clinical
benefit [17]. Since the EGb 761 extract contains many
compounds, including ginkgolides and the flavonoglyco-
sides myricetin and quercetin, it is not clear which indi-
vidual components of this extract are efficacious. Our
previous studies showed that pre-treatment with
ginkgolides protected against Aβ1–42-induced neuronal
death [18] and in the current study we tested the main
compounds in the EGb 761 extract on cultured neurons
and for their effects on synapse damage in response to
Aβ1–42. We report that pre-treatment of cultured neurons
with ginkgolides A or B significantly reduced the effects of
Aβ1–42 on synapses.
Results
Ginkgolides protect against Aβ1–42-induced synapse 
damage
Here we report that both Aβ1–42 and Aβ1–40 peptides, but
not the control peptide Aβ42-1, reduced the synaptophysin
content of cortical neurons in a dose-dependent manner.
While the synaptophysin content of cortical neurons was
reduced by 50% by 50 nM Aβ1–42, much higher amounts
of Aβ1–40 (2 µM) were required to have the same effect
(Figure 1). The effects of Aβ peptides on synapses were
apparent at concentrations that did not affect neuronal
survival. Since Aβ1–42 was the more potent peptide at dam-
aging synapses, all further experiments were carried out
using this peptide. Greater than 90% of this activity
remained after Aβ1–42 preparations were passed through a
100 Kd filter, or after high speed centrifugation (data not
shown), suggesting that the Aβ species responsible were
small soluble oligomers or proto-fibrils rather than the
Aβ1–42 causes a dose-dependent reduction in the synapto- physin content of neurons Figure 1
Aβ1–42 causes a dose-dependent reduction in the syn-
aptophysin content of neurons. The synaptophysin con-
tent of cortical neuronal cultures treated for 24 hours with 
varying concentrations of Aβ1–42 (solid circle), Aβ42-1 (hollow 
circle) or Aβ1–40 (solid triangle). Values shown are the mean 
synaptophysin content ± SD from 12 observations.
0
25
50
75
100
1 10 100 1000
Aβ (nM)
S
y
n
a
p
t
o
p
h
y
s
i
n
 
(
U
n
i
t
s
)Molecular Neurodegeneration 2008, 3:1 http://www.molecularneurodegeneration.com/content/3/1/1
Page 3 of 9
(page number not for citation purposes)
larger insoluble fibrils which this peptide sometimes
forms.
To determine if treatment with individual components of
Gingko biloba extracts could modify the effects of Aβ1–42,
cortical neurons were pre-treated with different concentra-
tions (0.001 to 10 µM) of the ginkgolides A or B, or the
flavanoglycosides (quercetin or myricetin) before the
addition of 200 nM Aβ1–42. Treatment of neuronal cul-
tures with these concentrations of ginkgolides A or B,
myricetin or quercetin did not affect their synaptophysin
content showing that these compounds alone do not
damage synapses or stimulate synaptogenesis. Pre-treat-
ment with either ginkgolide A or B reduced the effects of
Aβ1–42 on the synaptophysin content of neuronal cultures
(Figure 2). These effects were dose-dependent and the
ED50 (the concentration of drug that increased synapto-
physin content by 50% in Aβ1–42-treated neurons) was 40
nM for ginkgolide A and 10 nM for ginkgolide B. Pre-treat-
ment with either quercetin or myricetin did not affect the
loss of synaptophysin induced by Aβ1–42.
The synaptoprotective effect of ginkgolide B was competi-
tive; while the concentration of Aβ1–42 required to reduce
the synaptophysin content of untreated neurons by 50%
was 50 nM, 8 µM Aβ1–42 was required to have the same
effect in neurons treated with 1 µM ginkgolide B (Figure
3). This effect of ginkgolide B required pre-treatment;
there was no significant difference between the amount of
synaptophysin in neuronal cultures incubated with 200
nM Aβ1–42  and neuronal cultures in which 1 µM
ginkgolide B was added to neurons 30 minutes after the
addition of 200 nM Aβ1–42 (27 units ± 5 v 30 ± 4, n = 6, P
> 0.05).
The effects of ginkgolide B were not confined to cortical
neurons; the amounts of synaptophysin in hippocampal
neuronal cultures were also reduced by Aβ1–42. The
amount of Aβ1–42 required to reduce the synaptophysin
content of hippocampal neuronal cultures by 50% was 10
nM. Pre-treatment with 1 µM ginkgolide B resulted in
Aβ1–42  having a significantly reduced effect on the
amounts of synaptophysin in hippocampal cultures; in
these cultures the amount of Aβ1–42 required to reduce
synaptophysin content by 50% was increased to 4 µM
(Figure 4).
Ginkgolide B protects cortical neurons against Aβ1–42- induced loss of synaptophysin Figure 3
Ginkgolide B protects cortical neurons against Aβ1–
42-induced loss of synaptophysin. Primary cortical neu-
rons were pre-treated for 3 hours with control medium 
(solid circle) or with 1 µM ginkgolide B (hollow circle) and 
subsequently incubated for 24 hours with different concen-
trations of Aβ1–42 as shown. Each point represents the mean 
synaptophysin content ± SD from 9 observations.
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Effects of individual Ginkgo biloba components on Aβ1–42- induced loss of synaptophysin Figure 2
Effects of individual Ginkgo biloba components on 
Aβ1–42-induced loss of synaptophysin. The synapto-
physin content of cortical neuronal cultures pre-treated for 3 
hours with varying concentrations of ginkgolides A (hollow 
circle) or B (solid circle), myricetin (solid squares) or querce-
tin (hollow squares) and subsequently incubated with 200 nM 
Aβ1–42 for 24 hours. Values shown are the mean synapto-
physin content ± SD from 6 observations.
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Ginkgolides do not affect the binding of Aβ1–42 to neurons
The hypothesis that ginkgolide-treated neurons bind less
Aβ1–42 was tested by treating cortical neurons with bioti-
nylated-Aβ1–42. Firstly, we tested whether biotinylation
affected the activity of the Aβ1–42 peptide; there were no
significant differences in the synaptophysin content of
neuronal cultures treated with 200 nM Aβ1–42 and 200 nM
biotinylated-Aβ1–42 (28 units ± 4 v 27 ± 5, n = 6, P > 0.05).
Next, cortical neurons were treated with 1 µM ginkgolides
A or B prior to the addition of 200 nM biotinylated-Aβ1–
42. Neuronal extracts were collected at different time
points after the addition of peptide and the amounts of
cell bound biotinylated-Aβ1–42  were measured. The
amounts of biotinylated-Aβ1–42  increased in a time-
dependent manner over the first hour, but showed no sig-
nificant increases thereafter. There were no significant dif-
ferences in the amounts of biotinylated-Aβ1–42 ingested by
untreated cortical neurons and neurons treated with 1 µM
ginkgolides A or B (Figure 5).
PAF mimics the effects of Aβ1–42 on synaptophysin levels
Ginkgolides have been reported to antagonise PAF recep-
tors [19] raising the possibility that PAF mediates the syn-
apse damage caused by Aβ1–42. The addition of PAF, but
not lyso-PAF, mimicked the effects of Aβ1–42, and caused
a dose-dependent reduction in the synaptophysin content
of cortical neurons (Figure 6). The synaptophysin content
of cortical neurons was reduced by 50% by 5 nM PAF, a
concentration that did not affect neuronal survival. Pre-
treatment of neurons with 1 µM ginkgolides A or B, but
not with 25 µM myricetin or 25 µM quercetin, reduced the
effects of PAF on the synaptophysin content of neuronal
cultures (Figure 7).
These results are consistent with the hypothesis that
ginkgolides protect synapses via antagonism of PAF recep-
tors. Confirmation of this hypothesis was sought; pre-
treatment with the PAF antagonists, hexa-PAF or CV6209
also caused a dose-dependent increase in the amounts of
synaptophysin in neuronal cultures treated with 200 nM
Aβ1–42 (Figure 8). Next we examined the effects of pre-
treatment with a combination of ginkgolide B and hexa-
PAF. The amounts of synaptophysin in neuronal cultures
incubated with 200 nM Aβ1–42 was significantly increased
by pre-treatment with either 10 nM ginkgolide B (25 units
± 7 v 58 ± 3, n = 6, P < 0.05) or with 10 nM hexa-PAF B
Ginkgolides do not affect the incorporation of Aβ1–42 into  neurons Figure 5
Ginkgolides do not affect the incorporation of Aβ1–42 
into neurons. The amounts of biotinylated-Aβ1–42 in cell 
extracts from untreated neurons (hollow bars) or neurons 
pre-treated for 3 hours with ginkgolide A (solid bars) or 
ginkgolide B (striped bars) and subsequently incubated with 
200 nM biotinylated-Aβ1–42 for the time periods shown. Each 
point represents the mean amount of bound biotinylated-
Aβ1–42 (optical density × 1000) ± SD from 9 observations.
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Ginkgolide B protects hippocampal neurons against Aβ1–42- induced loss of synaptophysin Figure 4
Ginkgolide B protects hippocampal neurons against 
Aβ1–42-induced loss of synaptophysin. The synapto-
physin content of untreated hippocampal neurons (solid cir-
cle) or hippocampal neurons pre-treated for 3 hours with 1 
µM ginkgolide B (hollow circle) and subsequently incubated 
with different concentrations of Aβ1–42 for 24 hours as 
shown. Values shown are the mean synaptophysin content ± 
SD from 9 observations.
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(25 units ± 7 v 67 ± 6, n = 6, P < 0.05). Pre-treatment with
the combination of 10 nM ginkgolide B and 10 nM hexa-
PAF increased the synaptophysin content of cultures (74
units ± 4).
Ginkgolide B does not protect against PGE2-induced 
synapse damage
Since PAF has been shown to increase the production of
PGE2 from neurons in vitro [20] the effects of PGE2 on syn-
apses was examined. The synaptophysin content of corti-
cal neurons was significantly reduced following the
addition of PGE2, or with two prostanoid E (EP) receptor
agonists (butaprost or misoprostol). Pre-treatment of
neurons with 1 µM ginkgolide B did not protect against
the loss of synaptophysin in neuronal cultures incubated
with 40 nM PGE2, 1 µM butaprost or 1 µM misoprostol.
In contrast, the effects of PAF or Aβ1–42 on the synapto-
physin content of neuronal cultures were significantly
reduced by pre-treatment with 100 nM AH13205, an EP
receptor antagonist (Table 1).
Discussion
An in vitro model of Aβ-mediated synapse damage was
used to investigate the effects of individual components of
the Gingko biloba extract EGb 761 on the synapse damage
that occurs in AD. The addition of Aβ1–42, and to a lesser
extent Aβ1–40, reduced the synaptophysin content of corti-
cal and hippocampal neuronal cultures. The hippocam-
pus is thought to be involved in the formation of short
term memory, the loss of which is one of the earliest clin-
ical symptoms of AD [10]. In all assays, the effects of Aβ
peptides on the synaptophysin content of neuronal cul-
tures occurred at concentrations significantly lower than
those required to kill neurons. These observation are con-
sistent with in vivo observations that show that a loss of
synapses and a reduction in synaptophysin levels occurs
before any gross neurological damage is observed [8-11].
Although previous studies suggest that the flavonoglyco-
sides have protective properties against oxidative stress in
vitro [14,21], no protective effects of myricetin or querce-
tin against Aβ1–42-induced synapse damage were observed
in these studies. Moreover, flavonoglycosides have lim-
ited bioavailability after oral administration [14] suggest-
ing that these compounds are less likely to be responsible
for the protective effects of the EGb 761 extract. In con-
trast, nanomolar concentrations of both ginkgolides A
and B reduced the loss of synaptophysin induced by Aβ1–
42 in cortical neuronal cultures. Pre-treatment with 1 µM
ginkgolide B increased the amounts of Aβ1–42 required to
Ginkgolides A and B protect against PAF-mediated synapse  damage Figure 7
Ginkgolides A and B protect against PAF-mediated 
synapse damage. The synaptophysin content of untreated 
neurons (Con) (hollow squares) or neuronal cultures pre-
treated for 3 hours with 1 µM ginkgolides A or B or 25 µM 
myricetin or quercetin (solid squares) as shown and subse-
quently incubated with 25 nM PAF for 24 hours. Values 
shown are the mean synaptophysin content ± SD from 6 
observations.
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PAF, but not lyso-PAF, causes a dose-dependent loss of syn- aptophysin from neurons Figure 6
PAF, but not lyso-PAF, causes a dose-dependent loss 
of synaptophysin from neurons. The amounts of synap-
tophysin in cortical neurons treated with different concen-
trations of PAF (hollow circle) or lyso-PAF (solid circle) for 
24 hours. Each point represents the mean synaptophysin 
content ± SD from 9 observations.
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reduce the synaptophysin content of cortical neurons by
50% from 50 nM in untreated neurons to 8 µM in
ginkgolide B-treated neurons. The addition of Aβ1–42 also
damaged synapses in cultured hippocampal neurons; it
required only 10 nM Aβ1–42 to reduce the synaptophysin
content of these cultures by 50%. While it is tempting to
suggest that hippocampal neuronal synapses are more
sensitive to Aβ1–42 than cortical neuronal synapses a direct
comparison is invalid considering the differences in the
ages of mice used and the number of contaminating astro-
glial cells. In hippocampal neuronal cultures pre-treated
with ginkgolide B over 1 µM Aβ1–42 was needed to reduce
the synaptophysin content by 50%.
The mechanism of the protective effect of ginkgolides was
sought. We dismissed the simplest explanation, that
ginkgolides reduce the ability of neurons to bind Aβ pep-
tides, because ginkgolide-treated neurons ingested similar
amounts of biotinylated-Aβ1–42  as untreated neurons.
Aβ1–42 peptides exist in different states ranging from small
soluble oligomers or Aβ-derived diffusible ligands [5,6],
to larger fibrillar structures [4]. Therefore it is possible that
ginkgolides bind directly to Aβ1–42 peptides and promote
the formation of an inactive conformer. Although this
hypothesis cannot be totally excluded, ginkgolide-treated
cultures that had been washed (which removed any non-
bound ginkgolides) remained resistant to the synapse
damage induced by Aβ1–42. We note with interest an
observation that Aβ fibrillogenesis is accelerated in the
presence of plasma, endosomal and lysosomal mem-
branes, but reduced in Golgi membranes. The authors
suggested that the composition of these membranes
affected Aβ oligomerisation [22] and the possibility that
ginkgolides affect membrane composition and subse-
quently Aβ fibril formation within intracellular compart-
ments cannot be excluded.
Since Aβ peptides activate phospholipase A2 (PLA2) [23],
a major step in the production of PAF [24], the possibility
that synapse damage occurs as a consequence of Aβ1–42-
induced production of PAF was investigated. PAF recep-
tors are present in synapses [25] and PAF is required for
synapse maintenance [26] and long term potential in the
hippocampus [27]. However, higher concentrations of
PAF are implicated in neurodegenerative diseases includ-
ing AD [28]. Here we report that the addition of PAF
caused a dose-dependent reduction in the synaptophysin
Table 1: Ginkgolide B does not affect PGE2-induced loss of synaptophysin.
Synaptophysin content (units)
Pre-treatment
None Ginkgolide B (1 µM) AH13205 (100 nM)
None 100 ± 5 101 ± 3 102 ± 3
Aβ1–42 (200 nM) 24 ± 4 93 ± 7 97 ± 6
PAF (10 nM) 33 ± 7 78 ± 5 89 ± 8
PGE2 (40 nM) 41 ± 6 44 ± 7 96 ± 4
Butaprost (1 µM) 29 ± 5 37 ± 11 94 ± 7
Misprostal (1 µM) 32 ± 7 34 ± 6 98 ± 5
The effects of pre-treatment with ginkgolide B, or with the EP receptor antagonist AH13205 on the synaptophysin content of neuronal cultures 
incubated for 24 hours with Aβ1–42, PAF, PGE2, or with the EP receptors agonists butaprost or misoprostol as shown. Values shown are the mean 
synaptophysin content ± SD from 9 observations.
PAF antagonists protect against Aβ1–42 induced synapse dam- age Figure 8
PAF antagonists protect against Aβ1–42 induced syn-
apse damage. Cortical neurons were pre-treated with dif-
ferent concentrations of the PAF antagonists Hexa-PAF 
(solid circle) or CV6209 (hollow circle) for 3 hours prior to 
the addition of 100 nM Aβ1–42 for 24 hours. Values shown 
are the mean synaptophysin content, ± SD, of 9 observa-
tions.
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content of cortical neurons; 5 nM PAF reduced synapto-
physin content by 50%. The effects of PAF are transmitted
via a G-protein coupled receptor [29] and the addition of
lyso-PAF, a non-acetylated structural analogue of PAF that
does not bind to the PAF receptor, did not cause synapse
damage. One of the many reported effects of the
ginkgolides is antagonism of PAF receptors [19] and in the
current study we demonstrated that ginkgolide-treated
neurons were partially resistant to the effects of PAF, as
well as that of Aβ1–42, on synapses. The synapse-protective
effect of ginkgolide B was consistently stronger than
ginkgolide A, consistent with reports that ginkgolide B has
greater affinity for PAF receptors than ginkgolide A [30].
Pre-treatment with two non-related PAF antagonists,
hexa-PAF and CV6209 [31,32], also protected synapses
suggesting that antagonism of the PAF receptors mediates
the synaptoprotective effects of the ginkgolides. Although
pre-treatment with a combination of ginkgolide B and
hexa-PAF increased the synaptophysin content of cultures
relative to treatment with ginkgolide B or hexa-PAF alone,
their affects appeared to be additive rather than synergis-
tic.
Both Aβ1–42 and PAF, but not lyso-PAF, increased the pro-
duction of PGE2 in cortical neurons in vitro [20] raising the
possibility that the effects of PAF on synapses were medi-
ated through the production of PGE2. While pre-treat-
ment with ginkgolide B reduced both Aβ1–42 and PAF-
induced production of PGE2, it did not alter the effects of
PGE2, or two EP receptor agonists (butaprost or misopros-
tol), on the synaptophysin content of neuronal cultures.
In contrast, the EP receptor antagonist AH13205 [33] pro-
tected against Aβ1–42, PAF and PGE2-induced synapto-
physin loss. These results are consistent with the
hypothesis that ginkgolides protect against Aβ1–42-medi-
ated synapse damage by modifying the production of
PGE2. This hypothesis is also consistent with epidemio-
logical data that show that the use of cyclo-oxygenase
inhibitors reduce the severity of AD [34]. We suggest that
activation of PLA2 by Aβ1–42 leads to sustained production
of PAF which in turn increases PGE2 production, and that
high concentrations of PGE2 damaged synapses. PGE2
modulates synaptic transmission [35] and although high
concentrations were reported to induce apoptosis in hip-
pocampal neurons [36], we found that 10 µM PGE2 did
not kill cortical neurons (data not shown). Similarly we
found that although the EP receptor antagonist AH13205
reduced Aβ1–42-induced loss of synaptophysin it did not
affect Aβ1–42-induced neuronal death (data not shown).
It is worth noting that for many Ginkgo biloba extracts,
extraction procedures are used that optimise the fla-
vonoglycoside content. However, these procedures may
result in extracts that contain different amounts of
ginkgolides, and a recent analysis of commercial Ginkgo
biloba supplements by liquid chromatography/mass spec-
trometry demonstrated remarkable variations in
ginkgolide content [37]. Therefore, variations in the
ginkgolide content of different extracts may be a factor
that explains the variability of results obtained in clinical
studies.
Conclusion
In summary we show that sub-toxic concentrations of
Aβ1–42 damaged synapses in cultured cortical and hippoc-
ampal neurons. We propose that these changes model the
early stages of AD, where there are significant behavioural
changes including synaptic dysfunction and alterations in
the development of short-term memory, but before gross
neuronal loss is observed [38]. We report that neurons
treated with ginkgolides A or B show increased resistance
to the effects Aβ1–42  on synapses. This effect of the
ginkgolides correlated with their ability to antagonise PAF
receptors [30], and in these studies PAF also reduced the
synaptophysin content of cortical neuronal cultures.
Recent studies showed that the bioavailability of
ginkgolides after oral administration is high [14] suggest-
ing that the ginkgolides have the potential to reduce syn-
apse damage in AD should they be able to cross the blood
brain barrier and penetrate the central nervous system.
Methods
Neuronal cultures
Cortical neurons were prepared from the brains of day
15.5 C57BL/6J mouse embryos. After mechanical dissoci-
ation, cell sieving and isolation on histopaque (Sigma,
Poole, UK), neuronal precursors were plated at 2 × 105
cells/well in 48 well plates in Hams F12 containing 5%
foetal calf serum (FCS) for 2 hours. Cultures were then
shaken (600 r.p.m for 5 minutes) and non-adherent cells
removed by 2 washes in phosphate buffered saline (PBS).
Neurons were grown in neurobasal medium (NBM) con-
taining B27 components (Invitrogen, Paisley, UK) for 7
days. Immunostaining showed that the cells were greater
than 97% neurofilament positive. Less than 3% stained
for GFAP (astrocytes) or for F4/80 or CD14 (microglial
cells).
Hippocampal neuronal cultures were prepared from the
brains of adult C57BL/6J mice as previously described
[39]. Briefly, hippocampi were dissected from the adult
brain tissue and triturated with fire-polished pasteur
pipette in Hams F12 containing 5% FCS, 0.35% glucose,
0.025% trypsin, and 0.1% type IV collagenase (Invitro-
gen). After 30-minute incubation at 37°C, the cells were
shaken and the cell suspension was passed through a 100
µM cell strainer (Becton Dickenson). Cells were collected
by centrifugation, washed twice in Hams F12 containing
5% FCS, and plated at 2 × 105 cells/well in 48 well plates
for 24 hours. Cultures were shaken (600 r.p.m for 5 min-Molecular Neurodegeneration 2008, 3:1 http://www.molecularneurodegeneration.com/content/3/1/1
Page 8 of 9
(page number not for citation purposes)
utes) to remove non-adherent cells, washed twice with
PBS and the remaining cells were cultured in NBM con-
taining B27 components and 10 ng/ml glial-derived neu-
rotrophic factor (Sigma) for 7 days. Immunostaining
showed that after 7 days cultured in NBM less than 5% of
the viable cells stained for GFAP or F4/80 (astrocytes or
microglial cells). Both types of neuronal cultures were pre-
treated with test compounds for 3 hours. Cells were then
washed with PBS 3 times to remove unbound test com-
pounds before the addition of Aβ peptides in NBM/B27
components; the amounts of synaptophysin in treated
cultures were measured 24 hours later.
Cell extracts
Treated neurons were washed 3 times with PBS and
homogenised in a buffer containing 150 mM NaCl, 10
mM Tris-HCl, 10 mM EDTA, 0.2% SDS and mixed pro-
tease inhibitors (AEBSF, Aprotinin, Leupeptin, Bestain,
Pepstatin A and E-46) (Sigma) at 1 × 106 cells/ml. Nuclei
and cell debris was removed by centrifugation (300 × g for
5 minutes).
Synpatophysin ELISA
Synaptophysin levels in neuronal extracts were measured
by a sandwich ELISA as previously described [12]. In
short, the capture antibody (0.5 µg/ml) was a mouse
monoclonal antibody (mab) anti-synaptophysin
MAB368 (Chemicon, UK) and bound synaptophysin was
detected using a goat polyclonal anti-synaptophysin
(Abcam, Chandler's Ford, UK). Bound antibodies were
detected with a biotinylated anti-goat IgG (Dako, Cam-
bridgeshire, UK), extravidin-alkaline phosphatase and 1
mg/ml 4-nitrophenol phosphate in diethanolamine
buffer (Sigma). Absorbance was measured on a micro-
plate reader at 450 nM and the synaptophysin content
was calculated by reference to a standard curve. Samples
were expressed as "units synaptophysin" where 100 units
was arbitrarily defined as the amount of synaptophysin in
1 × 106 untreated cells. A standard curve was generated
from this sample using sequential log 2 dilutions (range
100 to 1.56 units).
Ingestion of biotinylated-Aβ1–42
Cortical neurons were pre-treated with drugs for 3 hours
and washed 3 times with PBS prior to the addition of
biotinylated-Aβ1–42. After 10, 30 or 60 minutes neurons
were washed a further three times with warm PBS to
remove unbound peptide and then homogenised in a
buffer containing 150 mM NaCl, 10 mM Tris-HCl, 10 mM
EDTA, 0.2% SDS and mixed protease inhibitors at 1 × 106
cells/ml. Nuclei and cell debris was removed by low speed
centrifugation (300 × g for 5 minutes). The amounts of
biotinylated-Aβ1–42 in cell extracts were determined by
ELISA. All stages of the ELISA were carried out at 37°C for
1 hr. Maxisorb Immunoplates (Nunc, Roskilde, Den-
mark) were coated with 0.1 µg mouse mab to Aβ1–42
(Immunodiagnostic Systems, Tyne and Wear, UK) as a
capture antibody. Samples were applied and the amounts
of biotinylated-Aβ1–42 bound were determined by incuba-
tion with extravidin-alkaline phosphatase and 1 mg/ml 4-
nitrophenol phosphate in diethanolamine buffer.
Absorbance was measured at 450 nM and the amounts of
biotinylated-Aβ1–42 in samples were expressed as optical
density (OD) × 1000.
Peptides
A peptide corresponding to amino acids 1 to 42 of the Aβ
protein (Aβ1–42), a biotinylated version containing biotin
at the terminal aspartic acid residue (biotinylated-Aβ1–42),
Aβ1–40 and a control peptide (Aβ42-1) were obtained from
Bachem (St Helens, UK). 1 mM stock solutions of peptide
were kept at -70°C, thawed on the day of use and soni-
cated prior to dilution and addition to cells.
Drugs
CV6209, ginkgolide B, myricetin, quercetin, platelet-acti-
vating factor (PAF), lyso-PAF, butaprost, misoprostol and
AH13025 were obtained from Sigma. Ginkgolide A, hexa-
PAF and PGE2, were obtained from Calbiochem (Notting-
ham, UK).
Statistical Analysis
Comparison of treatment effects were carried out using
one and two way analysis of variance techniques as appro-
priate. Post hoc comparisons of means were performed as
necessary.
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